Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development – Financial Post

VANCOUVER, British Columbia Products made by Vancouvers STEMCELL Technologies are now being used in over 30 COVID-19 studies worldwide. These studies are focusing on areas ranging from diagnostics and treatments to vaccine development and future prevention. STEMCELL is playing a crucial role in COVID-19 research by providing cutting-edge laboratory tools and reagents as well as through close collaborations with scientists. This will ultimately accelerate the pace of discovery and hopefully lead to a rapid resolution to the global pandemic.

At STEMCELL, we have a team of world-class scientists who have dedicated their careers to developing superior cell culture and cell isolation systems required to study devastating diseases, said Dr. Allen Eaves, STEMCELLs Founder, President, and CEO. It is always incredibly rewarding to see their hard work and expertise put to use. Every day were learning about new ways our customers are using our products to research solutions for the COVID-19 pandemic, and were actively working to support these researchers in any way we can.

STEMCELL is the global industry expert in developing systems for culturing human organoids, which are three-dimensional clusters of cells that closely resemble the biology of human organs. STEMCELL has partnered with an international team including Dr. Josef Penninger at the University of British Columbia, along with Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto, and Ali Mirazimis infectious biology team in Sweden. The group used STEMCELLs organoid systems in a study that examined how SARS-CoV-2 infects patients. Their findings, recently published in the top scientific journal Cell, provide insight into a potential treatment capable of stopping early infection of the novel coronavirus.

Human organoids enable us to better understand the pathology of this disease and to rapidly reach a therapeutic breakthrough. This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conders gastrointestinal group at STEMCELL Technologies, who have all been working tirelessly day and night for weeks, said Dr. Penninger.

Life science researchers and clinical labs also depend on STEMCELLs specialized cell isolation tools and instruments to extract the white blood cells responsible for immune responses from blood samples. Dr. James Crowe at the Vanderbilt Vaccine Center in Nashville, Tennessee is using a custom version of STEMCELLs EasySep system to isolate specific immune cells from the blood of COVID-19 survivors. Their goal is to rapidly develop antibody treatments and vaccines. This research group has used the same system to identify potential treatments for other viruses, including Ebola, chikungunya, HIV, dengue, norovirus, and respiratory syncytial virus.

STEMCELL listened to us when we came to them asking for custom tools to isolate the specific immune cells were working with from COVID-19 patients, said Dr. Crowe. We were able to integrate the new products and protocols into our research. In turn, we hand information about these products back to STEMCELL so that they can make it available to other labs. Its been a productive collaboration.

STEMCELL recently reported that researchers at Chinas Centre for Disease Control (CDC) successfully used STEMCELLs lung cell culture product, PneumaCultTM, to grow human lung airway cells and quickly obtain the viruss gene sequence, drastically shortening the path to vaccine development. Additionally, an international team including long-time STEMCELL collaborator Dr. Franois Jean at the University of British Columbia, an expert in antiviral drug discovery and emerging human viruses, is using STEMCELLs lung tissue culture system in a recently-funded study to develop and evaluate candidate therapeutics for COVID-19.

Solving medical challenges requires experts in science and medicine to work together with efficiency and accuracy, says Dr. Eaves. STEMCELL is proud to be a crucial component of this network by providing innovative tools, services, and expertise needed by our colleagues in research labs and clinical settings globally.

In addition to supporting rapid and groundbreaking developments for COVID-19 research, STEMCELLs products have been used successfully to study many other devastating viruses. This includes the use of PneumaCult to study respiratory viruses such as various coronaviruses, parvovirus, rhinovirus, respiratory syncytial virus, and influenza. Scientists have also successfully modeled microcephaly caused by Zika virus and cytomegalovirus using STEMCELLs BrainPhys and other products for neuroscience research. Similarly, STEMCELLs IntestiCult was used to study viruses targeting the intestinal system, including enteric coronavirus and norovirus. Finally, STEMCELLs EasySep reagents and RoboSep instrument have been central to studies of the immune response to viruses including HIV, Ebola, and dengue viruses.

About STEMCELL Technologies

STEMCELL Technologies is Canadas largest biotechnology company, with over 1,500 employees and year-on-year growth of approximately 20% for the last 26 years. Based in Vancouver, STEMCELL supports life sciences research around the world with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists advancing the stem cell, immunology, cancer, regenerative medicine, microbiology, and cellular therapy fields. Find more information at http://www.stemcell.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005200/en/

Contacts

Nicole Quinn, PhD Associate Director, Scientific Communications public.relations@stemcell.com

Excerpt from:
Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Financial Post

SNUH team finds causal gene of inherited retinal disorder – Korea Biomedical Review

A group of Korean researchers said they have confirmed a gene responsible for inherited retinal disorders (IRD) among Koreans.

IRD is a combination of several rare diseases that usually develops at a young age and progresses slowly over the lifetime. The patients gradually lose their sight, and most of them eventually lose their vision entirely due to continuous retinal cell degeneration.

The Seoul National University Bundang Hospital (SNUBH) Department of Ophthalmology and Seoul National University Hospital (SNUH) Department of Laboratory Medicine jointly conducted the study.

Currently, antioxidant therapy, artificial retinal transplantation, and stem cell therapy are being used to treat the disorder regardless of mutations, but the only viable treatment is gene therapy. Even when gene therapy is possible, only less than 1 percent of all IRD patients can be treated with it.

In the West, genetic abnormalities of these retinal diseases have been studied and known well. However, researches on Korean cases are still lacking, and the joint research team tackled the subject to find the causative gene for IRDs with 86 domestic patients, the team said in a news release on Wednesday.

The team studied and identified the gene responsible for the disorders by using the latest technique of gene analysis with the most number of patients who have been reported so far.

The study revealed that only 44 percent of the patients, 38 out of 86, possessed the causal gene for IRDs. Even among the patients with retinitis pigmentosa, the most common disorder among the IRDs, only 41 percent had the causative gene.

The causative genes could be quite diverse even in the same disorder. The patients can find a responsible gene only when they receive genetic counseling very actively and can receive gene counseling, too, the research team explained.

Differences were found in the type and frequency of causal gene mutations between Korean and Western cases. However, there were similarities between those of Korean and other Asian nations, including Japan.

The research and diagnosis environment for IRDs has been very poor until now, and our study has significance as a basic data for diagnosis and treatment for Korean patients with IRDs, SNUH Department of Ophthalmology Professor Woo Se-joon said.

Patients need to receive causal gene tests actively to provide the domestic medical communities with sufficient data, and a list of patients who can be treated. By doing so, clinical trials and new drug development in gene therapy will progress smoothly, he added.

Previously, only a few hospitals could diagnose the causative gene for IRDs and afford to test and treat IRD patients due to the high cost of genetic testing. Recently, however, the chance of diagnosis has increased as more hospitals are conducting genetic tests amid the lowered cost thanks to insurance benefits.

Also, the therapeutic opportunity for IRD patients is likely to get broadened, as the retinal pigment epithelium 65 gene (RPE65) therapy won approval from the U.S. Food and Drug Administration for the first time in the world.

Although we do not have a clear way to prevent IRDs at the moment, the prediction of risk and their early detection are developing through the discovery of family history and causative genes, Professor Woo said. Early diagnosis can prevent impaired vision by gene therapy and vision correction, and the patients will be able to choose appropriate jobs with social activities.

Also taking part in the research team were Professors Joo Kwang-sic and Park Kyu-hyung of SNUBH and Professors Seong Moon-woo and Park Sung-sup of SNUH.

The results of this study were published in the Journal of Korean Medical Science.

shim531@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Follow this link:
SNUH team finds causal gene of inherited retinal disorder - Korea Biomedical Review

FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19 – Cancer Network

The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with coronavirus disease 2019 (COVID-19), according to Celularity, the agents manufacturer.1

The company also announced that it will immediately begin a phase I/II clinical study of CYNK-001 in collaboration with Sorrento Therapeutics, which will include up to 86 patients with COVID-19.

We are confident that our strategic relationship with Sorrento will help assure our ability to meet the scale requirements for our efforts in COVID-19, Robert Hariri, MD, PhD, CEO for Celularity, said in a press release.

Individuals who are enrolled in the trial will receive infusions of natural killer (NK) cells, which the company believes could kill cells infected with the virus and address the resulting inflammation caused by the immune system.

Infectious Disease Research Institute (IDRI), a nonprofit based in Seattle, says it is coordinating the trial, which will take place at medical centers in the US.2

To date, efforts to treat COVID-19 cases have been primarily focused on antiviral medications, Corey Casper, MD, MPH, clinical professor of global health and medicine at the University of Washington and interim president and CEO at IDRI, said in a press release. While these are important, patients with serious disease may not respond completely to antiviral medications because they are experiencing damage already inflicted on the bodys vital organs.

CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells. The company suggests that using such cells eliminates the risk of an immune system reaction that other kinds of donor cells can cause.

The therapy is already being tested in patients with acute myeloid leukemia and multiple myeloma in early-stage studies, and as a potential treatment option for various solid tumors.

In January, the FDA cleared Celularitys investigational new drug (IND) application for CYNK-001 in patients with glioblastoma multiforme (GBM).3The clinical trial is anticipated to be the first clinical trial in the US to investigate intratumoral administration of an allogeneic NK cell therapy.

The FDA clearance of our IND validates the versatility of our allogeneic, off-the-shelf, placental-derived NK cell therapy platform to generate novel clinical candidates against a broad range of devastating cancers, Hariri said in a press release. This IND represents a significant step toward a potential immunotherapy option that is more accessible and tolerable to patients with glioblastoma multiforme.

According to the company, they expect to initiate first-in-human clinical testing of CYNK-001 administered either intravenously or intratumorally. The study is anticipated to evaluate the safety, feasibility, and tolerability of multiple doses of CYNK-001 in patients with relapsed GBM.

Nonclinical safety and efficacy data were presented at the 2019 Society for Neuro-Oncology (SNO) Annual meeting, demonstrating that a single administration of CYNK-001 was well-tolerated and showed enhancedin vivoanti-tumor activity against GBM.

References:

1. Sorrento to Provide Manufacturing Support to Celularity as CYNK-001 NK Cell Trial for COVID-19 Begins Enrolling Patients [news release]. San Diego, CA. Published April 2, 2020. globenewswire.com/news-release/2020/04/02/2010998/0/en/SORRENTO-TO-PROVIDE-MANUFACTURING-SUPPORT-TO-CELULARITY-AS-CYNK-001-NK-CELL-TRIAL-FOR-COVID-19-BEGINS-ENROLLING-PATIENTS.html. Accessed April 2, 2020.

2. Xconomy National. Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID. Xconomy National website. Published April 2, 2020. xconomy.com/national/2020/04/02/celularity-to-test-natural-killer-cell-therapy-for-cancer-against-covid/. Accessed April 2, 2020.

3. Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cyropreserved NK Cell Therapy [news release]. Warren, NJ. Published January 22, 2020. businesswire.com/news/home/20200122005061/en/Celularity-Announces-FDA-Clearance-Landmark-IND-CYNK-001. Accessed April 2, 2020.

Read more from the original source:
FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19 - Cancer Network

Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen – BioSpace

Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.

The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. Fate will advance the different candidates through preclinical studies to the point of the filing of an Investigational New Drug Application with the U.S. Food and Drug Administration. When that time comes, Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.

Fates iPSC platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses, according to the company. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said.

Under terms of the agreement, Fate will receive $50 million in upfront cash, as well as a $50 million equity investment by Janssen. Janssen will also cover the funding costs of the R&D of the collaboration candidates. Once Janssen takes over the program, Fate will then be eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones. Fate will also be eligible to receive double-digit royalties on worldwide commercial sales of products targeting the antigens. Additionally, Fate has the right to co-commercialize the candidates should they be approved and share equally in profits and losses, the company said in its announcement.

Scott Wolchko, president and chief executive officer of Fate Therapeutics, touted the partnership with Janssen. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies.

The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement.

Go here to see the original:
Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen - BioSpace

Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline – Business Wire

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotechs LentiBOOST for use in their CAR-T cell products.

CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing technology.

Under the terms of this agreement, SIRION agreed to provide Beam with non-exclusive access to its proprietary lentiviral transduction enhancer LentiBOOST for clinical development and commercialization of Beams portfolio of CAR-T programs. SIRION will be entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Dr. Christian Thirion, CEO and founder of SIRION Biotech GmbH explains: LentiBOOST was engineered to improve lentiviral transduction of difficult cell types like T-cells and hematopoietic stem cells. This technology enables robust upscaling of the T-cell production process, and helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product while at the same time improving clinical efficacy by increasing vector copy numbers (VCN) per cell. We are delighted that the LentiBOOST technology may help Beam further enhance the clinical success of its CAR-T pipeline.

LentiBOOST is used in an increasing number of clinical trials in the US and in Europe and the technology is more and more considered as a gold standard in manufacturing of cell products. Our non-exclusive licensing strategy makes our technology available to a wide range of companies and research hospitals to boost the efficiency of their various clinical programs, says SVP of Business Development & Licensing, Dr. Sabine Ott.

About SIRION Biotech GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the worlds most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

Continue reading here:
Beam Therapeutics Licenses SIRION Biotech's LentiBOOST Technology for its CAR-T pipeline - Business Wire

COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 – Science…

Complete study of the global Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Stem Cell Therapy market include _, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1636806/global-stem-cell-therapy-market

Segmental Analysis

The report has classified the global Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Stem Cell Therapy industry.

Global Stem Cell Therapy Market Segment By Type:

Autologous, Allogeneic

Global Stem Cell Therapy Market Segment By Application:

, Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Stem Cell Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Stem Cell Therapy market include _, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1636806/global-stem-cell-therapy-market

TOC

1 Market Overview of Stem Cell Therapy1.1 Stem Cell Therapy Market Overview1.1.1 Stem Cell Therapy Product Scope1.1.2 Market Status and Outlook1.2 Global Stem Cell Therapy Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Stem Cell Therapy Market Size by Region (2015-2026)1.4 Global Stem Cell Therapy Historic Market Size by Region (2015-2020)1.5 Global Stem Cell Therapy Market Size Forecast by Region (2021-2026)1.6 Key Regions Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.1 North America Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.2 Europe Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.3 China Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.5 Latin America Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Stem Cell Therapy Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Stem Cell Therapy Industry Impact1.7.1 How the Covid-19 is Affecting the Stem Cell Therapy Industry1.7.1.1 Stem Cell Therapy Business Impact Assessment Covid-191.7.1.2 Supply Chain Challenges1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Stem Cell Therapy Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-191.7.3.1 Government Measures to Combat Covid-19 Impact1.7.3.2 Proposal for Stem Cell Therapy Players to Combat Covid-19 Impact 2 Stem Cell Therapy Market Overview by Type2.1 Global Stem Cell Therapy Market Size by Type: 2015 VS 2020 VS 20262.2 Global Stem Cell Therapy Historic Market Size by Type (2015-2020)2.3 Global Stem Cell Therapy Forecasted Market Size by Type (2021-2026)2.4 Autologous2.5 Allogeneic 3 Stem Cell Therapy Market Overview by Type3.1 Global Stem Cell Therapy Market Size by Application: 2015 VS 2020 VS 20263.2 Global Stem Cell Therapy Historic Market Size by Application (2015-2020)3.3 Global Stem Cell Therapy Forecasted Market Size by Application (2021-2026)3.4 Musculoskeletal Disorder3.5 Wounds & Injuries3.6 Cornea3.7 Cardiovascular Diseases3.8 Others 4 Global Stem Cell Therapy Competition Analysis by Players4.1 Global Stem Cell Therapy Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Therapy as of 2019)4.3 Date of Key Manufacturers Enter into Stem Cell Therapy Market4.4 Global Top Players Stem Cell Therapy Headquarters and Area Served4.5 Key Players Stem Cell Therapy Product Solution and Service4.6 Competitive Status4.6.1 Stem Cell Therapy Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Osiris Therapeutics5.1.1 Osiris Therapeutics Profile5.1.2 Osiris Therapeutics Main Business and Companys Total Revenue5.1.3 Osiris Therapeutics Products, Services and Solutions5.1.4 Osiris Therapeutics Revenue (US$ Million) (2015-2020)5.1.5 Osiris Therapeutics Recent Developments5.2 NuVasive5.2.1 NuVasive Profile5.2.2 NuVasive Main Business and Companys Total Revenue5.2.3 NuVasive Products, Services and Solutions5.2.4 NuVasive Revenue (US$ Million) (2015-2020)5.2.5 NuVasive Recent Developments5.3 Chiesi Pharmaceuticals5.5.1 Chiesi Pharmaceuticals Profile5.3.2 Chiesi Pharmaceuticals Main Business and Companys Total Revenue5.3.3 Chiesi Pharmaceuticals Products, Services and Solutions5.3.4 Chiesi Pharmaceuticals Revenue (US$ Million) (2015-2020)5.3.5 JCR Pharmaceutical Recent Developments5.4 JCR Pharmaceutical5.4.1 JCR Pharmaceutical Profile5.4.2 JCR Pharmaceutical Main Business and Companys Total Revenue5.4.3 JCR Pharmaceutical Products, Services and Solutions5.4.4 JCR Pharmaceutical Revenue (US$ Million) (2015-2020)5.4.5 JCR Pharmaceutical Recent Developments5.5 Pharmicell5.5.1 Pharmicell Profile5.5.2 Pharmicell Main Business and Companys Total Revenue5.5.3 Pharmicell Products, Services and Solutions5.5.4 Pharmicell Revenue (US$ Million) (2015-2020)5.5.5 Pharmicell Recent Developments5.6 Medi-post5.6.1 Medi-post Profile5.6.2 Medi-post Main Business and Companys Total Revenue5.6.3 Medi-post Products, Services and Solutions5.6.4 Medi-post Revenue (US$ Million) (2015-2020)5.6.5 Medi-post Recent Developments5.7 Anterogen5.7.1 Anterogen Profile5.7.2 Anterogen Main Business and Companys Total Revenue5.7.3 Anterogen Products, Services and Solutions5.7.4 Anterogen Revenue (US$ Million) (2015-2020)5.7.5 Anterogen Recent Developments5.8 Molmed5.8.1 Molmed Profile5.8.2 Molmed Main Business and Companys Total Revenue5.8.3 Molmed Products, Services and Solutions5.8.4 Molmed Revenue (US$ Million) (2015-2020)5.8.5 Molmed Recent Developments5.9 Takeda (TiGenix)5.9.1 Takeda (TiGenix) Profile5.9.2 Takeda (TiGenix) Main Business and Companys Total Revenue5.9.3 Takeda (TiGenix) Products, Services and Solutions5.9.4 Takeda (TiGenix) Revenue (US$ Million) (2015-2020)5.9.5 Takeda (TiGenix) Recent Developments 6 North America Stem Cell Therapy by Players and by Application6.1 North America Stem Cell Therapy Market Size and Market Share by Players (2015-2020)6.2 North America Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe Stem Cell Therapy by Players and by Application7.1 Europe Stem Cell Therapy Market Size and Market Share by Players (2015-2020)7.2 Europe Stem Cell Therapy Market Size by Application (2015-2020) 8 China Stem Cell Therapy by Players and by Application8.1 China Stem Cell Therapy Market Size and Market Share by Players (2015-2020)8.2 China Stem Cell Therapy Market Size by Application (2015-2020) 9 Rest of Asia Pacific Stem Cell Therapy by Players and by Application9.1 Rest of Asia Pacific Stem Cell Therapy Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Stem Cell Therapy Market Size by Application (2015-2020) 10 Latin America Stem Cell Therapy by Players and by Application10.1 Latin America Stem Cell Therapy Market Size and Market Share by Players (2015-2020)10.2 Latin America Stem Cell Therapy Market Size by Application (2015-2020) 11 Middle East & Africa Stem Cell Therapy by Players and by Application11.1 Middle East & Africa Stem Cell Therapy Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Stem Cell Therapy Market Size by Application (2015-2020) 12 Stem Cell Therapy Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original post:
COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Science...

Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don – The Sun

A NURSEs life-saving stem cell transplant caused her to inherit her donors addiction for pickled onion flavour Monster Munch.

Claire Stewart, 49, had never tasted the snack before the treatment but as she recovered she developed cravings for it.

6

6

She started sending bemused husband David out to buy as many bags as he could.

She said: He thought it might be a passing urge like you get when youre pregnant, but those crisps became my favourite food.

Id never eaten them before. I preferred chocolate!

The mystery was solved when she met donor Keely Jackson, 37, whose bone marrow was matched with hers by charity Anthony Nolan.

Claire, of Middlesbrough, who needed a transplant to treat a rare blood cancer, gave nurse Keely thank you gifts and a pack of Monster Munch.

Claire said: Keely gave me the strangest look like I was playing some trick on her.

She told me shed always been a secret pickled onion Monster Munch addict.

RAIN ON OUR PARADEEaster weekend washout to hit after Britain basks in mini heatwave

'BLAST' PANIC'Explosions' heard as cops launch dramatic 'gun and drug' raid in London

'DEVASTATED'NHS nurse, 29, dies from coronavirus as pals pay tribute to 'amazing' medic

STAY STRONGCoronavirus survivors give hope for PM promising 'if we can beat it, so can he'

DRUG RAPGang leader named 'The General' jailed despite 150-mile move to halt life of crime

DEADLiest dayUK suffers worst leap in coronavirus deaths yet with 786 recorded in 24hrs

Id seemingly inherited this peculiar obsession from someone whose DNA I now share.

Keely, from Wakefield, West Yorks, said: Ive got a Monster Munch friend for life!

Rebecca Pritchard, of Anthony Nolan, said: From time to time, recipients do report developing tastes shared with their donor.

She added: While all of our activities are restricted at this time, we can still help people like Claire, with blood cancer, by joining the Anthony Nolan register online or donating to our emergency appeal.

Anthony Nolan needs to raise an extra 10,000 every month that the coronavirus pandemic goes on to continue to fund their work. Visit http://www.anthonynolan.org/coronavirusemergencyappeal.

6

6

6

6

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL exclusive@the-sun.co.uk

Read this article:
Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don - The Sun